What is Lifesci Capital’s Forecast for VERA FY2025 Earnings?

Vera Therapeutics, Inc. (NASDAQ:VERA) – Equities research analysts at Lifesci Capital lowered their FY2025 EPS estimates for Vera Therapeutics in a report issued on Wednesday, November 5th. Lifesci Capital analyst R. Katkhuda now forecasts that the company will post earnings of ($4.57) per share for the year, down from their previous forecast of ($4.44). The consensus estimate for Vera Therapeutics’ current full-year earnings is ($2.89) per share. Lifesci Capital also issued estimates for Vera Therapeutics’ Q4 2025 earnings at ($1.29) EPS.

Vera Therapeutics (NASDAQ:VERA) last announced its quarterly earnings data on Wednesday, November 5th. The company reported ($1.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.20) by ($0.06). During the same quarter in the previous year, the company earned ($0.85) earnings per share.

A number of other equities analysts have also recently commented on VERA. Wolfe Research reaffirmed a “peer perform” rating on shares of Vera Therapeutics in a research note on Monday, August 4th. Weiss Ratings restated a “sell (d-)” rating on shares of Vera Therapeutics in a report on Wednesday, October 8th. JPMorgan Chase & Co. lowered their price target on shares of Vera Therapeutics from $53.00 to $52.00 and set an “overweight” rating for the company in a report on Friday, November 7th. HC Wainwright increased their price target on shares of Vera Therapeutics from $85.00 to $90.00 and gave the company a “buy” rating in a research report on Monday. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Vera Therapeutics in a research report on Thursday, September 18th. Eight equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Vera Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $61.90.

Vera Therapeutics Trading Up 7.1%

NASDAQ VERA opened at $29.71 on Monday. The firm has a market cap of $1.90 billion, a PE ratio of -7.45 and a beta of 1.22. Vera Therapeutics has a 1-year low of $18.53 and a 1-year high of $51.61. The stock has a 50-day moving average of $27.60 and a 200-day moving average of $24.22. The company has a current ratio of 12.21, a quick ratio of 12.21 and a debt-to-equity ratio of 0.19.

Institutional Investors Weigh In On Vera Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the stock. Quantbot Technologies LP purchased a new position in shares of Vera Therapeutics during the second quarter valued at about $51,000. Quarry LP boosted its position in Vera Therapeutics by 25.0% during the 1st quarter. Quarry LP now owns 2,500 shares of the company’s stock valued at $60,000 after acquiring an additional 500 shares in the last quarter. AlphaQuest LLC boosted its position in Vera Therapeutics by 404.7% during the 1st quarter. AlphaQuest LLC now owns 4,007 shares of the company’s stock valued at $96,000 after acquiring an additional 3,213 shares in the last quarter. Virtus Investment Advisers LLC grew its holdings in shares of Vera Therapeutics by 14.8% during the 2nd quarter. Virtus Investment Advisers LLC now owns 4,176 shares of the company’s stock worth $98,000 after acquiring an additional 539 shares during the period. Finally, Tower Research Capital LLC TRC raised its position in shares of Vera Therapeutics by 192.9% in the 2nd quarter. Tower Research Capital LLC TRC now owns 4,186 shares of the company’s stock worth $99,000 after acquiring an additional 2,757 shares in the last quarter. 99.21% of the stock is owned by hedge funds and other institutional investors.

About Vera Therapeutics

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.